Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab Combinations in Advanced Solid Tumors
NCT02890069Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2016
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 7
01
Overview
Phase 1, open-label trial of spartalizumab in colorectal cancer (CRC), non-small cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC) and 1 more, sponsored by Novartis. Primary endpoints: Incidence of dose limiting toxicities at 5.5 years, Frequency of dose interruptions and reductions at 5.5 years and 3 more. Started Oct 2016; status: completed.
02
Drugs
spartalizumab
03
Conditions
colorectal cancer (CRC)non-small cell lung carcinoma (NSCLC)triple-negative breast cancer (TNBC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02890069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02890069.